Navigation Links
Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
Date:12/18/2018

Nativis, Inc., a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM.

The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site.

“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”

The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.

“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”

Rivera concluded, “We are looking forward to obtaining data from this ongoing clinical study for treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families.”

About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.

Media Contact:
Dennis Kroft
dkroft(at)nativis(dot)com
201-602-8354

Read the full story at https://www.prweb.com/releases/nativis_announces_publication_of_study_in_patients_with_recurrent_glioblastoma_rgbm/prweb15991523.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Nanomedical Diagnostics Announces Office Move to Accommodate Company Growth
2. Urological Associates of Southern Arizona Announces Dr. Kenneth Choi’s Designation as UroLift® Center of Excellence
3. Fastec Imaging Announces OEM Partner Program
4. EARTHRES Adds to Executive Team - Announces New Chief Operating Officer
5. Cloudponics Announces Holiday Discount For Leading Product, GroBox
6. Immuno-Oncology 360° (IO360°) NYC Gathering Announces Keynotes for the 5th Annual Event
7. FDAnews Announces — Early Bird Pricing Ends on Nov. 8 for Emerging Trends in Medical Device Regulation and Quality, Dec. 6, 2018, Washington, DC
8. Karius Announces the Clinical Investigator Award for Applied Pediatric Infectious Disease Genomics
9. Myoscience Announces Commercial Release of Nerve Stim Enabled iovera° Smart Tip
10. Slone Partners, Where People Are Our Science®, Announces Insights: Scientific Healthcare Investing 2018 Panel Event With Leaders In The Investment Community
11. Ajinomoto Health & Nutrition's Amino Acid Division Announces Price Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... ... March 07, 2019 , ... Murrieta Genomics , the genomic sequencing business ... presented by University of California Riverside’s EPIC SBDC focused on research funding by U.S. ... on Tuesday, March 17, 2019. The location is the Highlander Union Building, Room 302 ...
(Date:3/9/2019)... ... 2019 , ... Hello Bio announces the launch of novel ... studying GPCR and DREADD signalling. Hello Bio has been granted a license from ... and Stroke, both institutes of the National Institutes of Health, as well as ...
(Date:2/27/2019)... ... 26, 2019 , ... Circulomics is launching the Short Read Eliminator Kit ... sequencing library preparation. , This kit enhances long-read sequencing read lengths by using ... is not damaged and recovered with high efficiency. Short DNA up to 25 kb ...
Breaking Biology News(10 mins):
(Date:2/12/2019)... SAN FRANCISCO (PRWEB) , ... February 12, 2019 ... ... (CRO) specializing in dermatology, has finalized a deal to extend their use of ... diagnostics clinical trials, through 2023. The CRO has been a regular Medrio customer ...
(Date:2/2/2019)... ... January 31, 2019 , ... Dust off your Doc Martens, Virun ... the Nuriv 2019 Expo West Music and Tech Festival at the ESports Arena in ... in the natural foods, beverages, and dietary supplement industries, the Nuriv Music and Tech ...
(Date:2/2/2019)... ... February 01, 2019 , ... Stay on top of current hot topics through ... Access to all webinars is free, so be sure to register today to save ... http://www.xtalks.com to check out our upcoming webinars, or click below to learn more ...
(Date:1/30/2019)... ... January 29, 2019 , ... Actus Therapeutics, ... dosing of the first patient in a phase 1/2 clinical study of ACTUS-101 ... with high morbidity and often leads to premature death. There are variable ...
Breaking Biology Technology: